These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21455660)

  • 21. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
    Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
    Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
    Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up.
    Paschoalin RP; Torregrosa JV; Sánchez-Escuredo A; Barros X; Durán CE; Campistol JM
    Transplant Proc; 2012 Nov; 44(9):2588-9. PubMed ID: 23146463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study.
    Bonet J; Bayés B; Fernández-Crespo P; Casals M; López-Ayerbe J; Romero R
    Clin Nephrol; 2011 Mar; 75(3):181-7. PubMed ID: 21329627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.
    Charytan C; Coburn JW; Chonchol M; Herman J; Lien YH; Liu W; Klassen PS; McCary LC; Pichette V
    Am J Kidney Dis; 2005 Jul; 46(1):58-67. PubMed ID: 15983958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism.
    van der Plas WY; Engelsman AF; Özyilmaz A; van der Horst-Schrivers AN; Meijer K; van Dam GM; Pol RA; de Borst MH; Kruijff S
    Ann Surg Oncol; 2017 Jan; 24(1):15-22. PubMed ID: 27459979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcimimetics versus parathyroidectomy: What is preferable?
    Rroji M; Spasovski G
    Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
    Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
    Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.
    Fukagawa M; Fukuma S; Onishi Y; Yamaguchi T; Hasegawa T; Akizawa T; Kurokawa K; Fukuhara S
    Clin J Am Soc Nephrol; 2012 Sep; 7(9):1473-80. PubMed ID: 22822017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysphoria induced in dialysis providers by secondary hyperparathyroidism.
    Soomro IH; Goldfarb DS
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):9-11. PubMed ID: 25516914
    [No Abstract]   [Full Text] [Related]  

  • 33. Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.
    Ichii M; Ishimura E; Okuno S; Chou H; Kato Y; Tsuboniwa N; Nagasue K; Maekawa K; Yamakawa T; Inaba M; Nishizawa Y
    Nephron Clin Pract; 2010; 115(3):c195-202. PubMed ID: 20413997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes in patients with renal hyperparathyroidism requiring cinacalcet pre-operatively followed by parathyroidectomy.
    Baker D; Sevak S; Callahan RE; Czako PF; Lloyd LR; Nagar S
    Am J Surg; 2019 Jan; 217(1):146-151. PubMed ID: 29929906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.
    St Peter WL; Li Q; Liu J; Persky M; Nieman K; Arko C; Block GA
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):354-60. PubMed ID: 19129318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of secondary hyperparathyroidism in hemodialysis patients: the key role of native vitamin D supplementation.
    Jean G; Vanel T; Terrat JC; Chazot C
    Hemodial Int; 2010 Oct; 14(4):486-91. PubMed ID: 20955282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report.
    Takada D; Tsukamoto T; Fuse M; Kada S; Yanagita M
    BMC Nephrol; 2017 Oct; 18(1):315. PubMed ID: 29047366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of calcimimetics in the treatment of hyperparathyroidism.
    Wüthrich RP; Martin D; Bilezikian JP
    Eur J Clin Invest; 2007 Dec; 37(12):915-22. PubMed ID: 18036025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
    Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.